Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in ...
Indiatimes10h
Sree Rayalaseema Hi-Strength Hypo Share Price
Sree Rayalaseema Hi-Strength Hypo Ltd., incorporated in the year 2005, is a Small Cap company (having a market cap of Rs 1,342.29 Crore) operating in Chemicals sector. Sree Rayalaseema Hi-Strength ...